Information pervades the universe, yet means nothing. Meaning emerged when matter organized into systems that could ...

A new research paper reframes the simulation hypothesis, asking whether reality could be simulated and what science can test.

This is “bigger” than the ChatGPT moment, Lieberman wrote to me. “But Pandora’s Box hasn’t been opened for the rest of the ...

Author Shawn Peters blends clarity and rigor to make data structures and algorithms accessible to all learners. COLORADO, CO, UNITED STATES, January 2, 2026 /EINPresswire.com/ — Vibrant Publishers ...

2026 is highlighted as the year of the singularity with Elon Musk warning of underestimated impacts; conversations with him ...

Insilico now has a pipeline of more than 40 AI-developed drugs it is developing for conditions such as cancer, bowel and kidney disease.

2025 has come and gone. It was an interesting year and had its fair share of weird Vancouver stories. We’ve gone through some posts from throughout the year and selected some of the weirdest and ...

Last week, two of the biggest and oldest companies in the burgeoning AI drug discovery space announced a surprise merger. In a roughly 75-25 deal, Recursion Bio and Exscientia will (if the merger goes ...

AI models are getting so good at finding vulnerabilities that some experts say the tech industry might need to rethink how ...

Recursion Pharmaceuticals (RXRX) added ~11% in the morning trading on Wednesday after J.P. Morgan upgraded the AI-driven biotech to Overweight from Neutral, citing a blockbuster sales potential for ...

When I last covered the self-styled TechBio company Recursion Pharmaceuticals, Inc. (RXRX) in early October, I was attempting to find reasons why the company's share price was on the rise, up from ~$4 ...

In one of the biggest M&A deals involving artificial intelligence-focused drug developers to date, Recursion Pharma has agreed to join with Exscientia in an all-stock transaction valued at $688 ...